May 2026 DS

In this edition:NICE updates: ruxolitinib and glycopyrronium creamLDOM in paediatric patientsA Delphi consensus on chronic prurigoA systematic review of dupilumab-associated facial and neck erythemaZinc deficiency in bullous pemphigoidDeterminants of real-world sunscreen effectivenessDoes gamification improve training?Ruxolitinib ‘super responders’ in vitiligo treatmentOestrogen therapy for menopausal hair loss?European SCC guidelines

Does Senital Node Biopsy improve survival in melanoma patients?Co-treating Ixekizumab With Tirzepatide - does it enhance response?Adjuvant cemiplimab in high-risk SCC, does it help?Do we need to do CXR before starting methotrexate?How effective are systemics at controlling generalised pustular psoriasis?Stage IIC vs IIIA melanoma survival analysis

Salt immersion as a treatment for wartsTargeted reapplication of treatment for scabies in infantsChanges to Advice and Guidance in NHS EnglandWeekly or daily bathing in patients with eczema?Which devices to use in patient teledermoscopy?Does AI improve FDS in real world application?LPP guidance from EADVHep B guidance for patients on systemics

Highlights:A new way of thinking about diagnosing mosaic pigmentary disordersNail melanoma and melanonychia - length of monitoring and changes to look out forCutaneous immune-related adverse events and oncological outcomesA Delphi consensus on Topical Steroid WithdrawalEuropean HS guidelinesFrontal Fibrosing Alopecia in men : a systematic reviewValidated tools to help with suspected drug allergies and how to approach allergy labellingHydrocolloid dressing vs petroleum ointment application post op - how do they compare?

AGA GuidelinesThere is a large void when it comes to guidelines for the treatment of androgenetic alopecia, specifically FPHL. In this final lesson, we bring it all together, with recently published 2025 guidelines that help to fill that void and provide worldwide guidance, reflecting common practice in the UK and elsewhere.

Platelet Rich Plasma (PRP)Some clinicians swear by it, others have had a less favourable experience with it. So, what’s the low-down on PRP for FPHL?

Low Level Laser Light Therapy (LLLT)Everyone’s talking about it. But should we be recommending it? And if so, which devices? How often? Let’s review the recent evidence.

Low Dose Oral Minoxidil (LDOM)There is a lot of hype around LDOM and it is increasingly used for all types of alopecia. But, what doses should we use? Do we need to monitor it? And what are the side effects? We summarise the evidence here.

When should we do blood tests? Which tests? And how?This lesson summarises consensus views on blood tests for FPHL and how to do testing when required. Based on dermatology as well as endocrinological guidelines and papers, we bring summarise the salient points.

Today on Dermatology Snapshots, we are looking at the New England Journal of Medicine 2025 Clinical Practice review on Female-Pattern Hair Loss by Dr. Elise Olsen. It’s a condition that affects up to 12% of women in their thirties, and over half of women over seventy.